ESPREsperion Therapeutics, Inc.

ESPR Stock Price, Valuation & Chart | Esperion Therapeutics, Inc.

$3.180+0.00 (+0.00%)

At close · 13 July 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic ESPR intrinsic value ESPR calculated fair value vs price

Overview Financials Dividends Ratios

ESPR Historical price chart

ESPR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization661.15M

PE Ratio-53.0

EPS-0.06

Trading Volume0

Today's High/Low3.18/3.18

Dividend Yield0.00

52 Week High/Low4.17/1.13

Shares Outstanding207.91M

ESPR Financial Statement

ESPR Analyst ratings

ESPR Analysis & performance metrics

ESPR Company profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.…

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial…

ESPR Management team

Name

Position

Sheldon L. KoenigCEO

President, Chief Executive Officer & Director

Benjamin Halladay M.B.A.CFO

Chief Financial Officer

Glenn P. Brame

Chief Technical Operations Officer

Stephen Pinkosky

Vice President of Drug Discovery of Early Pre-Clinical Development

Tiffany Aldrich M.B.A.CTO

Associate Director of Corporate Communications

Betty Jean Swartz

Chief Business Officer

Benjamin O. Looker J.D.

General Counsel & Corporate Secretary

Name

Position

Sheldon L. KoenigCEO

President, Chief Executive Officer & Director

Benjamin Halladay M.B.A.CFO

Chief Financial Officer

Glenn P. Brame

Chief Technical Operations Officer

Stephen Pinkosky

Vice President of Drug Discovery of Early Pre-Clinical Development

Tiffany Aldrich M.B.A.CTO

Associate Director of Corporate Communications

Betty Jean Swartz

Chief Business Officer

Benjamin O. Looker J.D.

General Counsel & Corporate Secretary

Management Team

Sheldon L. KoenigCEO

President, Chief Executive Officer & Director

Benjamin Halladay M.B.A.CFO

Chief Financial Officer

Glenn P. Brame

Chief Technical Operations Officer

Stephen Pinkosky

Vice President of Drug Discovery of Early Pre-Clinical Development

Tiffany Aldrich M.B.A.CTO

Associate Director of Corporate Communications

Betty Jean Swartz

Chief Business Officer

Benjamin O. Looker J.D.

General Counsel & Corporate Secretary

Management

Sheldon L. KoenigCEO

President, Chief Executive Officer & Director

Benjamin Halladay M.B.A.CFO

Chief Financial Officer

Glenn P. Brame

Chief Technical Operations Officer

Stephen Pinkosky

Vice President of Drug Discovery of Early Pre-Clinical Development

Tiffany Aldrich M.B.A.CTO

Associate Director of Corporate Communications

Betty Jean Swartz

Chief Business Officer

Benjamin O. Looker J.D.

General Counsel & Corporate Secretary

Total 7 executives

ESPR Frequently asked questions

What is Esperion Therapeutics, Inc. (ESPR) Stock Price?

Current stock price of Esperion Therapeutics, Inc. (ESPR) stock is $3.180. The stock price is +0.00% higher in the session. The intraday range can be seen from this page. Volume of Esperion Therapeutics, Inc. (ESPR) stock is 0.

Last updated at 13 July 2026, 08:00 pm.

Why is the Esperion Therapeutics, Inc. (ESPR) stock price going up or down today?

The stock price of Esperion Therapeutics, Inc. (ESPR) can change with earnings, company news, and overall market sentiment. Esperion Therapeutics, Inc. operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Esperion Therapeutics, Inc. stock expensive at its current price?

Whether Esperion Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ESPR on this page is -53.00. EPS on this page is -0.06. Compare those figures with peers and growth expectations before deciding if the current Esperion Therapeutics, Inc. price is justified.

How has the stock price of Esperion Therapeutics, Inc. (ESPR) performed historically?

Historical performance for Esperion Therapeutics, Inc. (ESPR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ESPR reacted to past earnings and market events.

Should I buy Esperion Therapeutics, Inc. (ESPR) stock, at this price?

Buying Esperion Therapeutics, Inc. (ESPR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.